BSD Medical has reported the positive study results of its BSD-2000 hyperthermia system, which is used to treat cancer.
The BSD-2000 hyperthermia system delivers localised therapeutic heating by applying radiofrequency energy to the tumour.
The open-label comparative cohort study enrolled 60 patients with locally advanced and unresectable pancreatic cancer, and showed that patients treated using the hyperthermia system had an improved survival rate with no increase in toxicity.
The company is currently conducting a clinical study to evaluate the safety and efficacy of hyperthermia using the BSD-2000 combined with radiotherapy for the treatment of patients suffering from locally advanced, persistent or recurrent deep tumours of the pelvis.
BSD has also applied for a humanitarian device exemption approval for the device.
